Sivik Global Healthcare LLC Makes New Investment in Repligen Corporation $RGEN

Key Points

• Sivik Global Healthcare LLC initiated a 20,000-share position in Repligen worth approximately $3.85 million, while institutional investors collectively own 97.64% of the company.
• Analysts maintain a generally positive outlook, with a consensus “Moderate Buy” rating and an average price target of $173.21; individual targets range up to $185.
• Repligen reported quarterly EPS of $0.54, beating estimates of $0.45, while revenue rose 11.9% year over year to $204.13 million. Shares recently traded at $177.51, near the analyst consensus target.

Sivik Global Healthcare LLC bought a new position in Repligen Corporation (NASDAQ:RGEN - Free Report) during the third quarter, according to its most recent disclosure with the SEC. The institutional investor bought 20,000 shares of the biotechnology company's stock, valued at approximately $3,845,000. Repligen accounts for about 2.4% of Sivik Global Healthcare LLC's holdings, making the stock its 20th biggest holding.

Other institutional investors also recently modified their holdings of the company. Bank of Nova Scotia bought a new position in Repligen during the 2nd quarter valued at approximately $3,547,000. American Capital Management Inc. purchased a new position in Repligen during the second quarter valued at $49,262,000. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in Repligen in the second quarter worth $1,173,000. Avidity Partners Management LP boosted its holdings in Repligen by 54.7% in the first quarter. Avidity Partners Management LP now owns 77,800 shares of the biotechnology company's stock worth $9,166,000 after acquiring an additional 27,500 shares in the last quarter. Finally, Tidal Investments LLC boosted its holdings in Repligen by 75.2% in the second quarter. Tidal Investments LLC now owns 8,863 shares of the biotechnology company's stock worth $1,209,000 after acquiring an additional 3,803 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the company. JPMorgan Chase & Co. raised their price target on Repligen from $165.00 to $175.00 and gave the company an "overweight" rating in a report on Wednesday, July 29th. Benchmark upgraded shares of Repligen from a "hold" rating to a "buy" rating and set a $185.00 target price on the stock in a research note on Tuesday, July 7th. Zacks Research cut shares of Repligen from a "strong-buy" rating to a "hold" rating in a report on Monday, September 28th. Weiss Ratings upgraded shares of Repligen from a "hold (c-)" rating to a "hold (c)" rating in a report on Thursday. Finally, UBS Group reissued a "buy" rating on shares of Repligen in a research report on Tuesday, September 29th. Two analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $173.21.

Repligen Stock Performance

RGEN traded up $5.00 during midday trading on Tuesday, hitting $177.51. 408,085 shares of the company traded hands, compared to its average volume of 1,043,482. The company has a quick ratio of 7.64, a current ratio of 9.05 and a debt-to-equity ratio of 0.26. The firm has a market capitalization of $10.02 billion, a PE ratio of 242.55, a price-to-earnings-growth ratio of 3.17 and a beta of 1.08. The company's 50-day moving average is $174.23 and its 200 day moving average is $143.90. Repligen Corporation has a 52 week low of $100.99 and a 52 week high of $198.87.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its quarterly earnings results on Tuesday, July 28th. The biotechnology company reported $0.54 EPS for the quarter, topping analysts' consensus estimates of $0.45 by $0.09. Repligen had a net margin of 5.29% and a return on equity of 5.30%. The firm had revenue of $204.13 million during the quarter, compared to analyst estimates of $201.59 million. During the same period in the previous year, the business posted $0.26 earnings per share. The business's revenue for the quarter was up 11.9% on a year-over-year basis. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. On average, research analysts expect that Repligen Corporation will post 2.06 EPS for the current year.

About Repligen

Repligen Corporation NASDAQ: RGEN develops and supplies bioprocessing technologies used by biopharmaceutical manufacturers to produce biological drugs, including monoclonal antibodies, recombinant proteins, vaccines and cell and gene therapies. Its products are used throughout the manufacturing process, from laboratory and process development through commercial-scale production.

The company's portfolio includes chromatography products and protein A ligands and resins, filtration and fluid-management systems, single-use technologies, process analytics and other consumables and equipment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.